In a filing, Aquestive Therapeutics Inc revealed its Chief Innovation/Tech Officer Schobel Alexander Mark unloaded Company’s shares for reported $0.3 million on Mar 15 ’24. In the deal valued at $6.00 per share,50,000 shares were sold. As a result of this transaction, Schobel Alexander Mark now holds 984,476 shares worth roughly $4.39 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Schobel Alexander Mark sold 25,000 shares, generating $129,685 in total proceeds. Upon selling the shares at $5.19, the Chief Innovation/Tech Officer now owns 1,040,371 shares.
Leerink Partners initiated its Aquestive Therapeutics Inc [AQST] rating to an Outperform in a research note published on May 10, 2024; the price target was $8. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in mid April with a ‘”an Overweight”‘ rating. Raymond James began covering AQST with “an Outperform” recommendation on March 28, 2024.
Price Performance Review of AQST
On Friday, Aquestive Therapeutics Inc [NASDAQ:AQST] saw its stock jump 3.48% to $4.46. Over the last five days, the stock has gained 5.19%. Aquestive Therapeutics Inc shares have risen nearly 120.79% since the year began. Nevertheless, the stocks have risen 149.16% over the past one year. While a 52-week high of $6.23 was reached on 03/18/24, a 52-week low of $1.25 was recorded on 01/02/24. SMA at 50 days reached $3.20, while 200 days put it at $3.09.
Levels Of Support And Resistance For AQST Stock
The 24-hour chart illustrates a support level at 4.34, which if violated will result in even more drops to 4.21. On the upside, there is a resistance level at 4.57. A further resistance level may holdings at 4.67. The Relative Strength Index (RSI) on the 14-day chart is 67.37, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.54, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 14.72%. Stochastics%K at 86.95% indicates the stock is a selling.
How much short interest is there in Aquestive Therapeutics Inc?
A steep rise in short interest was recorded in Aquestive Therapeutics Inc stocks on 2024-07-31, growing by 3.16 million shares to a total of 10.79 million shares. Yahoo Finance data shows the prior-month short interest on 2024-06-28 was 7.63 million shares. There was a rise of 29.25%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 22, 2019 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating.
